ADMA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-05

• Through our ADMA BioManufacturing business segment, we currently have three products with U.S. Food and Drug Administration (the “FDA”) approval, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), an intravenous immune …

• We are also developing a pipeline of plasma-derived therapeutics, including a product related to its issued U.S. Patent Nos. 10,259,865, 11,084,870, 11,897,943 and 12,612,450 pertaining to methods of treatment and prevention of S. pneumoniae infection using an immunoglobulin manufactured to contain …

• We manufacture our commercial products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000 liters (the “Boca Facility”). Based on current production yields, our completed and ongoing supply chain…

• Through our ADMA BioCenters subsidiary, we currently operate seven source plasma collection facilities in the U.S., all of which hold FDA licenses. This business unit, which we refer to as our Plasma Collection Centers business segment, provides us with a significant portion of the blood plasma requ…

• The increase in total revenue was primarily driven by the $19.6 million increase in ASCENIV sales, reflecting continued growth in market acceptance of the product, alongside an increase of $0.7 million in Plasma Collection Centers sales and a $0.4 million increase in intermediates and other products…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• Through our ADMA BioManufacturing business segment, we currently have three products with U.S. Food and Drug Administration (the “FDA”) approval, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), an Intravenous Immune …

• We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000 liters (the “Boca Facility”). Based on current production yields, our completed and ongoing supply chain enhancem…

• Through our ADMA BioCenters subsidiary, we currently operate seven source plasma collection facilities in the U.S., all of which hold FDA licenses. This business unit, which we refer to as our Plasma Collection Centers business segment, provides us with the blood plasma required for the manufacture …

• The decrease in total revenue was primarily driven by the $18.1 million reduction in BIVIGAM sales driven by lower volume as a result of competitive pressures in the standard immune globulin industry, and by the $3.0 million decrease in Intermediates and other products revenue, driven by the discont…

• Gain on sale of plasma centers was $8.0 million for the three months ended March 31, 2026, as result of the sale of three of our plasma centers, completed during the period.

Text added vs the prior filing · source: 10-Q · 2026-08-05

• On July 10, 2026, plaintiff Lisa Mazzarino filed a putative securities class action lawsuit against the Company, Adam Grossman, our director, President and Chief Executive Officer, Jerrold Grossman, our Vice Chairman of the Board, and Brad Tade, our former Chief Financial Officer and Treasurer, in t…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• We may become subject to certain legal proceedings and claims arising in connection with the normal course of our business. In the opinion of management, there are currently no material pending legal proceedings that would have a material adverse effect on our consolidated financial position, result…

Text added vs the prior filing · source: 10-Q · 2026-08-05

• We and certain of our directors and officers have been named as defendants in a securities class action lawsuit. This litigation, and any similar or related proceedings that may be filed in the future, could result in substantial costs, divert management’s attention and resources from our business, …

• contractors may not be able to execute our inspection procedures and required tests appropriately or timely, and we may be reliant on a single or limited number of contract laboratories;

• We and certain of our directors and officers have been named as defendants in a securities class action lawsuit. This litigation, and any similar or related proceedings that may be filed in the future, could result in substantial costs, divert management’s attention and resources from our business, …

• On July 10, 2026, a putative securities class action lawsuit, Mazzarino v. ADMA Biologics, Inc. et al., Case No. 2:26-cv-06918 (D.N.J.), was filed against us and certain of our directors and officers. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934…

• We may also become subject to additional securities class action lawsuits, stockholder derivative actions, regulatory inquiries, investigations or other proceedings arising out of the same or similar allegations.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• contractors may not be able to execute our inspection procedures and required tests appropriately;

• Our product candidates will require significant additional research and clinical trials, and we will need to overcome significant regulatory burdens prior to commercialization in the United States and other countries. In addition, we may be required to spend significant funds on building out our com…

• On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities…

• Our ability to use our net operating loss carryforwards (“NOLs”) may be limited.

• We have incurred substantial losses during our history. As of December 31, 2025, we had federal and state NOLs of $265.6 million and $176.9 million, respectively. Federal and state NOLs of approximately $33.4 million and $62.0 million, respectively, will begin to expire at various dates beginning in…

Text added vs the prior filing · source: 10-Q · 2026-08-05

• On August 3, 2026, we entered into an amendment (the “Kohler Amendment”) to that certain Employment Agreement, dated November 25, 2025, by and between us and Paul Terence Kohler, Jr., our Chief Financial Officer and Treasurer (the “Kohler Employment Agreement”).

• The Kohler Amendment amends the Kohler Employment Agreement to provide that, beginning August 1, 2026, we will provide Mr. Kohler with a monthly stipend of $10,000, net of taxes, for up to 18 months, subject to extension upon approval by our Board, to be used for temporary housing in the Boca Raton,…

• The Kohler Amendment also amends the severance provisions of the Kohler Employment Agreement. As amended, in the event Mr. Kohler’s employment is terminated by us without Cause or by Mr. Kohler for Good Reason (as each term is defined in the Kohler Employment Agreement), Mr. Kohler will be entitled …

• The foregoing description of the Kohler Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Kohler Amendment, a copy of which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q and is incorporated by reference into this Item 5.